FONTANA, DILETTA

FONTANA, DILETTA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 28 (tempo di esecuzione: 0.021 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 02 - Intervento a convegno 2014 DONADONI, CARLAPIAZZA, ROCCO GIOVANNIFONTANA, DILETTAPIROLA, ALESSANDRAREDAELLI, SARASPINELLI, ROBERTAMAGISTRONI, VERAGAIPA, GIUSEPPEPERONACI, MARCOELLI, ELENA MARIAGAMBACORTI PASSERINI, CARLO +
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 02 - Intervento a convegno 2014 Ceccon, MMologni, LPiazza, RPirola, AFontana, DGambacorti-Passerini, C +
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 02 - Intervento a convegno 2015 Piazza, RPirola, ADonadoni, CFontana, DRedaelli, SGambacorti-Passerini, C +
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 02 - Intervento a convegno 2015 Piazza, RPirola, ADonadoni, CFontana, DRedaelli, SFarina, FGambacorti-Passerini, C +
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 02 - Intervento a convegno 2015 Mologni, LCeccon, MFontana, DPirola, APiazza, RGambacorti-Passerini, C
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 01 - Articolo su rivista 2015 FONTANA, DILETTACECCON, MONICAGAMBACORTI PASSERINI, CARLOMOLOGNI, LUCA
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 99 - Altro 2015 Ceccon M.Mologni L.Piazza R.Pirola A.Fontana D. +
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 01 - Articolo su rivista 2015 GAMBACORTI PASSERINI, CARLODONADONI, CARLAPIROLA, ALESSANDRAREDAELLI, SARAFONTANA, DILETTASPINELLI, ROBERTAMAGISTRONI, VERAPERONACI, MARCOPIAZZA, ROCCO GIOVANNI +
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 01 - Articolo su rivista 2015 PIAZZA, ROCCO GIOVANNIPIROLA, ALESSANDRAFONTANA, DILETTAMAGISTRONI, VERABORIN, LORENZA MARIAGAMBACORTI PASSERINI, CARLO +
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 01 - Articolo su rivista 2015 CECCON, MONICAMOLOGNI, LUCAPIAZZA, ROCCO GIOVANNIPIROLA, ALESSANDRAFONTANA, DILETTAGAMBACORTI PASSERINI, CARLO +
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 02 - Intervento a convegno 2017 Farina, FCeccon, MMori, SVerga, LBorin, LMMologni, LFontana, DGEETA, GEETAPiazza, RGambacorti-Passerini, C
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 02 - Intervento a convegno 2018 Fontana, DMauri, MMassimino, LBossi, MCITTERIO, STEFANIACavaletti, GGambacorti-Passerini, CPiazza, R +
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 02 - Intervento a convegno 2018 D. FontanaM. MauriL. MassiminoG. ZambrottaM. BossiS. CitterioG. CavalettiC. Gambacorti-PasseriniR. Piazza +
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 01 - Articolo su rivista 2018 Passerini CGFontana D +
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 01 - Articolo su rivista 2019 Magistroni, VMauri, MD'Aliberti, DCrespiatico, IFontana, DSharma, NPirola, ARedaelli, SMassimino, LKhandelwal, PCitterio, SViltadi, MBombelli, SRigolio, RPerego, RGambacorti Passerini, CPiazza, R +
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 02 - Intervento a convegno 2019 Bossi ESteidl CFontana DSharma GGMologni LPiazza RGGambacorti Passerini C +
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 02 - Intervento a convegno 2019 Diletta FontanaDaniele RamazzottiAndrea AroldiLuca MassiminoElena Maria ElliMonica FumagalliRocco PiazzaCarlo Gambacorti-Passerini +
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 07 - Tesi di dottorato Bicocca post 2009 2019 FONTANA, DILETTA
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 01 - Articolo su rivista 2020 Fontana D.Crespiatico I.D'Aliberti D.Massimino L.Bertagna M.Zambrotta G.Bossi M.Fanelli F.Cassina V.Salerno D.Nardo L.Chinello C.Mantegazza F.Magni F.Cavaletti G.Gambacorti-Passerini C.Piazza R. +
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 01 - Articolo su rivista 2020 Mori S.Antolini L.Fontana D.Piazza R.Gambacorti Passerini C. +